Enovix Announces Proposed $300 Million Offering of Convertible Senior Notes Due 2030
ENOV(NYSE:ENOV) September 10, 2025 September 10, 2025
September 10, 2025Finance
Read more →Enovix Shareholder Third Reminder: Early Warrant Expiration Price Condition
ENOVEnovix Warrants: 17 of 17 Trading Days Above $10.50 Enovix Warrants: 17 of 17 Trading Days Above $10.50
August 13, 2025Warrants
Read more →Enovix Shareholder Second Reminder: Early Warrant Expiration Price Condition
ENOVEnovix Warrants: 14 of 14 Trading Days Above $10.50 Enovix Warrants: 14 of 14 Trading Days Above $10.50
August 8, 2025Warrants
Read more →Enovis to Participate in Upcoming Investor Conferences
ENOVWilmington, DE, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences:
August 8, 2025Investor
Read more →Enovis Announces Second Quarter 2025 Results
ENOVWilmington, DE, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended July 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.
August 7, 2025Earnings
Read more →Canaccord Genuity Maintains Buy on Enovis, Lowers Price Target to $70
ENOVMay 14, 2025
Read more →Where Enovis Stands With Analysts
ENOVMay 9, 2025
Read more →JMP Securities Maintains Market Outperform on Enovis, Lowers Price Target to $55
ENOVMay 9, 2025
Read more →Needham Maintains Buy on Enovis, Lowers Price Target to $57
ENOVMay 9, 2025
Read more →Enovis Lowers FY2025 Adj EPS Guidance from $3.10-$3.25 to $2.95-$3.10 vs $3.18 Est; Raises FY2025 Sales Guidance from $2.19B-$2.22B to $2.22B-$2.25B vs $2.21B Est
ENOVMay 8, 2025
Read more →Enovis Q1 2025 Adj. EPS $0.81 Beats $0.74 Estimate, Sales $558.83M Miss $558.90M Estimate
ENOVMay 8, 2025
Read more →Needham Reiterates Buy on Enovis, Maintains $64 Price Target
ENOVApril 9, 2025
Read more →Needham Reiterates Buy on Enovis, Maintains $64 Price Target
ENOVApril 2, 2025
Read more →Enovis Appoints Damien McDonald as CEO, Effective May 12 2025, Following Matt Trerotola's Retirement
ENOVApril 2, 2025
Read more →Needham Maintains Buy on Enovis, Lowers Price Target to $64
ENOVFebruary 27, 2025
Read more →Enovis Expects 2025 Revenue Of Approximately $2.19B-$2.22B, Compared To Consensus Of $2.22B, With Adjusted EPS Of $3.10-$3.25 Vs. $3.16 Est.
ENOVFebruary 26, 2025
Read more →Enovis Says Matt Trerotola Will Retire From His Position As CEO, The Board Is Actively Working With An Executive Search Firm To Identify The Company's Next CEO
ENOVFebruary 26, 2025
Read more →Enovis Q4 2024 Adj EPS $0.98 Beats $0.92 Estimate, Sales $560.98M Beat $555.15M Estimate
ENOVFebruary 26, 2025
Read more →Enovis Expects 2024 Adjusted EPS Of $2.75-$2.80 Versus Prior Expectations Of $2.62-$2.77 And Consensus Of $2.71
ENOVNovember 6, 2024
Read more →Enovis Narrowed Its Revenue Range And Adjusted EBITDA Expectations For 2024, With Sales Estimated At $2.1B Vs. $2.11B Est. And Adjusted EBITDA Of $373M-$378M Versus Prior Guidance Of $368M-$383M
ENOVNovember 6, 2024
Read more →Enovis Q3 2024 Adj EPS $0.73 Beats $0.62 Estimate, Sales $505.22M Beat $504.07M Estimate
ENOVNovember 6, 2024
Read more →Evercore ISI Group Initiates Coverage On Enovis with Outperform Rating, Announces Price Target of $68
ENOVSeptember 12, 2022
Read more →Canaccord Genuity Initiates Coverage On Enovis with Buy Rating, Announces Price Target of $67
ENOVSeptember 12, 2022
Read more →